Runben Biotechnology (SH:603193) NORTHEAST SECURITIES·2025-04-30 02:18Investment Rating - The report maintains a "Buy" rating for the company [3][5]. Core Insights - The company achieved a revenue of 1.318 billion yuan in 2024, representing a year-on-year growth of 27.61%, with a net profit of 300 million yuan, up 32.80% [1][9]. - The company has diversified its product offerings and expanded its sales channels, leading to sustained revenue growth [2][14]. - The company plans to distribute a cash dividend of 2.30 yuan per 10 shares (tax included) [1]. Financial Performance Summary - In 2024, the company reported a revenue of 1.318 billion yuan, with a breakdown by product: mosquito repellent products generated 439 million yuan (33.33% of total revenue, +35.39%), baby care products 690 million yuan (52.36%, +32.42%), essential oils 158 million yuan (11.97%, +7.88%), and other products 30 million yuan (2.27%, -25.51%) [2][10]. - The company’s online direct sales accounted for 58.72% of total revenue, amounting to 774 million yuan, with a growth of 24.84% [2][10]. - The company’s expense ratio increased to 31.57% in 2024, up 1.35 percentage points, primarily due to increased marketing and financial expenses [11][12]. Future Projections - Revenue projections for 2025-2027 are estimated at 1.711 billion yuan, 2.175 billion yuan, and 2.728 billion yuan, respectively, with net profits expected to be 392 million yuan, 496 million yuan, and 613 million yuan [3][14]. - The company’s projected price-to-earnings (PE) ratios for 2025, 2026, and 2027 are 40x, 32x, and 26x, respectively [3][14].